[Chemotherapy for thymic carcinoma]

Area of Science:

• Oncology
• Thoracic Surgery
• Medical Oncology

Context:

• Thymic epithelial neoplasms (TNEs) encompass thymoma, thymic carcinoma, and thymic neuroendocrine carcinoma.
• Thymic carcinoma and neuroendocrine carcinoma are rare malignancies, comprising only 1-4% of anterior mediastinal tumors.
• These rare tumors are often referred to as "orphan tumors" due to the lack of established clinical management standards, including chemotherapy.

Purpose:

• To review current and potential chemotherapeutic strategies for thymic carcinoma and thymic neuroendocrine carcinoma.
• To evaluate the biological rationale and clinical efficacy of different chemotherapy regimens.
• To identify optimal treatment approaches for advanced or refractory thymic epithelial neoplasms.

Summary:

• Current palliative chemotherapy for advanced thymic carcinoma and neuroendocrine carcinoma often uses cisplatin-based regimens adapted from thymoma treatment, despite biological differences.
• Platinum doublet chemotherapy with third-generation agents is proposed as a potentially less toxic and equally effective first-line option for thymic carcinoma.
• Single-agent chemotherapy may be considered for second-line or later treatment, while molecular targeted agents are still under investigation.

Impact:

• This review highlights the need for evidence-based treatment guidelines for rare thymic malignancies.
• It suggests a shift towards platinum doublet chemotherapy for first-line treatment of thymic carcinoma, aiming to balance efficacy and toxicity.
• The findings underscore the ongoing research into molecular targeted therapies for improved patient outcomes.